Hypertension Clause Samples

Hypertension. The following services related to hypertension are covered with $0 Out-of-Pocket Cost when linked to a primary diagnosis of hypertension and performed by a Network Provider: • Office visits to a Primary Care Provider for routine management of hypertension • Office visits to a Cardiologist (heart specialist) for consultation and routine management of Hypertension • Office visits to a Nephrologist (kidney specialist) for consultation and routine management of Hypertension • Palliative care conversations (chronic condition treatment preferences) with Primary Care Provider, Cardiologist, or Nephrologist • Nutritional counseling up to six (6) visits per year • Targeted laboratory tests for the routine management of hypertension Please note, if you have complications from hypertension and use an emergency department or urgent care center, have a Hospital stay, or get treatment for heart and kidney disease, services will be subject to standard Out-of-Pocket Costs as outlined in your Schedule of Benefits.

Hypertension. Expanded pharmacy coverage is limited to $0 Out-of-Pocket Cost for select Tier 1 preferred generic medications and a reduction in Out-of-Pocket Cost for select Tier 2 and Tier 3 preferred brand medications as outlined below. On plans that apply a Deductible for Tier 2 and Tier 3 medications, the Deductible is waived and the Coinsurance or Copayment is reduced by half. On plans that have a copay for Tier 2 and Tier 3 medications, the copay is reduced by half.

Hypertension. Section 5-145a C.G.S. is amended to include peace officers covered under Section 29-18, 29-18a, 29-18b, C.G.S. or Section 26-5 C.G.S. and fulltime firefighting personnel.

Hypertension i. The number of enrollees identified as hypertensive using HEDIS measures ii. Percentage who received a blood test for cholesterol or LDL.

Hypertension. Heart Failure with Preserved Ejection Fraction (HFpEF)

Hypertension. There are at least 970 million people worldwide who have hypertension, with approximately 330 million people in the developed world and 640 million in the developing world documented as having hypertension [242]. The WHO rates hypertension as one of the most important causes of premature death worldwide and the problem is growing. In 2025 it is estimated there will be 1.56 billion adults living with high blood pressure [242]. Hypertension increases the risk for many CV diseases, including stroke, coronary artery disease, heart failure, and peripheral vascular disease [243]. Coronary disease in men and stroke in women are the principal CV events noted after hypertension onset, as reported by the Framingham Heart Study [244].

Hypertension. Expanded pharmacy coverage is limited to $0 Out-of-Pocket Cost for select Tier 1 preferred generic medications and a reduction in Out-of-Pocket Cost for select Tier 2 and Tier 3 preferred brand medications as outlined below. On plans that apply a Deductible for Tier 2 and Tier 3 medications, the Deductible is waived and the Coinsurance or Copayment is reduced by half. On plans that have a copay for Tier 2 and Tier 3 medications, the copay is reduced by half. covered under this reduced Out-of-Pocket Cost benefit. Select medications used to treat hypertension that are specified on our formulary and are approved by the FDA are covered under this reduced Out-of-Pocket Cost

Hypertension. SAMPLE The following services related to hypertension are covered with $0 Out - of- Pocket Cost when linked to a primary diagnosis of hypertension and performed by a Network Provider: • Office visits to a Primary Care Provider for routine management of hypertension • Office visits to a Cardiologist (heart specialist) for consultation and routine management of Hypertension • Office visits to a Nephrologist (kidney specialist) for consultation and routine management of Hypertension • Pallia tive care conversations (chronic condition treatment preferences) with Primary Care Provider, Cardiologist, or Nephrologist • Nutritional counseling up to six (6) visits per year • Targeted l aboratory tests for the routine management of hypertension Please not e, if you have complications from hypertension and use an emergency department or urgent care center , have a Hospital stay, or get treatment for heart and kidney disease, services will be subject to standard Out - of- Pocket Costs as outlined in your Schedule of Benefits .

Hypertension. Hypertension, or worsening of pre-existing hypertension, can occur with the use of binimetinib. Blood pressure should be measured at baseline and monitored during treatment, with control of hypertension by standard therapy as appropriate. In case of severe hypertension, temporary interruption of binimetinib is recommended until hypertension is controlled (see Table 2 in section 4.2). VTE can occur when binimetinib is administered (see section 4.8). Binimetinib should be used with caution in patients who are at risk for, or who have a history of VTE. If during treatment patient develops VTE or pulmonary embolism, it should be managed with dose interruption, reduction or treatment discontinuation (see Table 1 in section 4.2). Pneumonitis/ILD can occur with binimetinib. Treatment with binimetinib should be withheld in patients with suspected pneumonitis or ILD, including patients presenting new or progressive pulmonary symptoms or findings such as cough, dyspnoea, hypoxia, reticular opacities or pulmonary infiltrates (see Table 1 in section 4.2). Binimetinib should be permanently discontinued in patients diagnosed with treatment related pneumonitis or ILD. New primary malignancies, cutaneous and non-cutaneous, have been observed in patients treated with BRAF inhibitors and can occur when binimetinib is administered in combination with encorafenib (see section 4.8).